Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV alphavaccine
- Development stage
- Preclinical
- Lead developer
- AlphaVax
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
RSV alphavaccine is an investigational vaccine candidate developed by AlphaVax for the prevention of respiratory syncytial virus (RSV) infection. It utilizes a proprietary alphavirus replicon particle (VRP) technology derived from the Venezuelan Equine Encephalitis (VEE) virus. These VRPs are engineered to be replication-defective and serve as a delivery vehicle for RNA encoding RSV-specific antigens. By targeting dendritic cells in vivo, the vaccine induces high levels of antigen expression, triggering both potent T-cell mediated immunity and neutralizing antibody responses against the virus. The platform is designed to provide a robust immune response without the risk of viral propagation or disease associated with live-attenuated vaccines.
- Other names
- RSV VRP vaccineRSV RNA particle vaccineAlphaVax RSV vaccine
02
Targets
RSV G (Respiratory syncytial virus attachment glycoprotein)
Beyond the preview
Go deeper on RSV alphavaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV alphavaccine.